Literature DB >> 16785118

Action of botulinum neurotoxins in the central nervous system: antiepileptic effects.

Y Bozzi1, L Costantin, F Antonucci, M Caleo.   

Abstract

Botulinum neurotoxins (BoNTs) are metalloproteases which act on nerve terminals and cause a long-lasting inhibition of neurotransmitter release. BoNTs act by cleaving core proteins of the neurotransmitter release machinery, namely the SNARE (soluble NSF-attachment receptors) proteins. The action of BoNTs in the peripheral nervous system (PNS) has been extensively documented, and knowledge gained in this field laid the foundations for the use of BoNTs in human disorders characterized by hyperfunction of peripheral nerve terminals. Much less is known about the action of BoNTs on the central nervous system (CNS). In vitro studies have demonstrated that BoNTs can affect the release of several neurotransmitters from central neurons. Recent studies have provided the first characterization of the effects of BoNT/E on CNS neurons in vivo. It has been shown that BoNT/E injected into the rat hippocampus inhibits glutamate release and blocks spike activity of pyramidal neurons. Intrahippocampal injection of BoNT/E resulted in significant inhibition of seizure activity in experimental models of epilepsy, suggesting a potential therapeutic use of BoNTs in the CNS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785118     DOI: 10.1007/bf03033939

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  52 in total

1.  Regulation of dendritic protein synthesis by miniature synaptic events.

Authors:  Michael A Sutton; Nicholas R Wall; Girish N Aakalu; Erin M Schuman
Journal:  Science       Date:  2004-06-25       Impact factor: 47.728

2.  Poisoning by botulinum neurotoxin A does not inhibit formation or disassembly of the synaptosomal fusion complex.

Authors:  H Otto; P I Hanson; E R Chapman; J Blasi; R Jahn
Journal:  Biochem Biophys Res Commun       Date:  1995-07-26       Impact factor: 3.575

3.  Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia.

Authors:  F Gilio; A Currà; C Lorenzano; N Modugno; M Manfredi; A Berardelli
Journal:  Ann Neurol       Date:  2000-07       Impact factor: 10.422

4.  Localization of sites for 125I-labelled botulinum neurotoxin at murine neuromuscular junction and its binding to rat brain synaptosomes.

Authors:  J O Dolly; R S Williams; J D Black; C K Tse; P Hambleton; J Melling
Journal:  Toxicon       Date:  1982       Impact factor: 3.033

5.  Microtubule-dissociating drugs and A23187 reveal differences in the inhibition of synaptosomal transmitter release by botulinum neurotoxins types A and B.

Authors:  A C Ashton; J O Dolly
Journal:  J Neurochem       Date:  1991-03       Impact factor: 5.372

Review 6.  When should temporal-lobe epilepsy be treated surgically?

Authors:  Susan S Spencer
Journal:  Lancet Neurol       Date:  2002-10       Impact factor: 44.182

7.  Toxicity of botulinum neurotoxins in central nervous system of mice.

Authors:  Siro Luvisetto; Ornella Rossetto; Cesare Montecucco; Flaminia Pavone
Journal:  Toxicon       Date:  2003-03       Impact factor: 3.033

8.  Internalization and proteolytic action of botulinum toxins in CNS neurons and astrocytes.

Authors:  C Verderio; S Coco; O Rossetto; C Montecucco; M Matteoli
Journal:  J Neurochem       Date:  1999-07       Impact factor: 5.372

Review 9.  Neurotoxins affecting neuroexocytosis.

Authors:  G Schiavo; M Matteoli; C Montecucco
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

10.  Clostridial neurotoxins and substrate proteolysis in intact neurons: botulinum neurotoxin C acts on synaptosomal-associated protein of 25 kDa.

Authors:  L C Williamson; J L Halpern; C Montecucco; J E Brown; E A Neale
Journal:  J Biol Chem       Date:  1996-03-29       Impact factor: 5.157

View more
  16 in total

Review 1.  Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.

Authors:  Ying C Li; Ege T Kavalali
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

Review 2.  Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

3.  Single intracerebroventricular injection of botulinum toxin type A produces slow onset and long-term memory impairment in rats.

Authors:  Zdravko Lacković; Veseljka Rebić; Peter F Riederer
Journal:  J Neural Transm (Vienna)       Date:  2009-08-20       Impact factor: 3.575

4.  Convection-enhanced delivery of botulinum toxin serotype A into the nonhuman primate cisterna magna and hippocampus.

Authors:  Davis P Argersinger; Stuart Walbridge; Nicholas M Wetjen; Alexander O Vortmeyer; Tianxia Wu; John A Butman; John D Heiss
Journal:  J Neurosurg       Date:  2019-07-19       Impact factor: 5.115

Review 5.  Advances in the application of technology to epilepsy: the CIMIT/NIO Epilepsy Innovation Summit.

Authors:  Steven C Schachter; John Guttag; Steven J Schiff; Donald L Schomer
Journal:  Epilepsy Behav       Date:  2009-09       Impact factor: 2.937

6.  Long-lasting attenuation of amygdala-kindled seizures after convection-enhanced delivery of botulinum neurotoxins a and B into the amygdala in rats.

Authors:  Maciej Gasior; Rebecca Tang; Michael A Rogawski
Journal:  J Pharmacol Exp Ther       Date:  2013-06-14       Impact factor: 4.030

Review 7.  Convection-enhanced delivery in the treatment of epilepsy.

Authors:  Michael A Rogawski
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

8.  Intranasal Delivery of Botulinum Neurotoxin A Protects against Hippocampal Neuron Death in the Lithium-Pilocarpine Rat Model.

Authors:  Zhi Huang; Yajun Lian; Yuan Chen; Shuang Li; Haifeng Zhang; Nanchang Xie; Yake Zheng; Shouyi Wu; Yuhan Wang; Wenchao Cheng; Qiaoman Zhang; Chengze Wang; Yinping Shi; Na Xie
Journal:  Neurochem Res       Date:  2019-03-14       Impact factor: 3.996

9.  The role of activity in synaptic degeneration in a protein misfolding disease, prion disease.

Authors:  Matteo Caleo; Laura Restani; Eleonora Vannini; Zuzana Siskova; Hussain Al-Malki; Ruth Morgan; Vincent O'Connor; V Hugh Perry
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

10.  Transient synaptic silencing of developing striate cortex has persistent effects on visual function and plasticity.

Authors:  Matteo Caleo; Laura Restani; Laura Gianfranceschi; Laura Costantin; Chiara Rossi; Ornella Rossetto; Cesare Montecucco; Lamberto Maffei
Journal:  J Neurosci       Date:  2007-04-25       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.